Genital Herpes Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The market size of Genital Herpes is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as AiCuris, Heidelberg ImmunoTherapeutics, BioNTec, EMS, Novartis Pharmaceuticals, Astellas Pharma Inc, Vical, GlaxoSmithKline, Genocea Biosciences, Inc., Agenus Inc., Starpharma Pty Ltd, Endo Pharmaceuticals, AiCuris Anti-infective Cures AG, NeurogesX.

[Nevada, United States] - DelveInsight's "Genital Herpes Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Genital Herpes, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Genital Herpes Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/genital-herpes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Genital Herpes Market Report:
The Genital Herpes market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In April, 2024: ModernaTX, Inc. announced that the purpose of their study is to generate safety and immunogenicity data and establish a proof-of-concept of clinical benefit of the mRNA-1608 vaccine candidate.
In April, 2024: GlaxoSmithKline announced that the purpose of this first-time-in-human (FTiH) study is to evaluate the reactogenicity, safety, immune response, and efficacy of an investigational herpes simplex virus (HSV)-targeted immunotherapy (TI). The study will be conducted in 2 parts: Part I assessing different formulations of the Herpes Simplex Virus-targeted immunotherapy (HSVTI) in healthy participants aged 18-40 years; Part II assessing the 2 formulations of the HSVTI in participants aged 18-60 years with recurrent genital herpes.
According to the recent national estimates from the 2015-2016 National Health and Nutrition Examination Survey (NHANES), the age adjusted seroprevalence of HSV-1 and HSV-2 antibody prevalence among persons aged 14-49 was 48.1% and 12.1% respectively.
According to the study conducted by Marchi et al. (2017), the seroprevalence of HSV-1 and HSV-2 was estimated in the general population of Siena (central Italy). In adults, the seroprevalence of HSV1 and HSV -2 was estimated to be 70% and 11.5%, respectively.
The total prevalent HSV infected cases in the United States were nearly 87,877,000 in 2023.
Among EU4 and the UK, Germany accounted for the highest HSV infected total prevalent cases with approximately 27,959,000 cases, while France had the lowest total prevalence with around 15,832,000 cases in 2023.
Key Genital Herpes Companies are as follows: AiCuris, Heidelberg ImmunoTherapeutics, BioNTec, EMS, Novartis Pharmaceuticals, Astellas Pharma Inc, Vical, GlaxoSmithKline, Genocea Biosciences, Inc., Agenus Inc., Starpharma Pty Ltd, Endo Pharmaceuticals, AiCuris Anti-infective Cures AG, NeurogesX.
Key Genital Herpes Therapies are as follow: Famciclovir, Aciclovir, valacyclovir, ASP2151, AIC316, Capsaicin Dermal Patch.
Launching multiple stage Genital Herpes pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Genital Herpes market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/genital-herpes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Genital Herpes Overview:
Herpes simplex virus (HSV), known as herpes, is a common infection that can cause painful blisters or ulcers. It primarily spreads by skin-to-skin contact. It is treatable but not curable. There are two types of herpes simplex virus. Type 1 (HSV-1) mostly spreads by oral contact and causes infections in or around the mouth (oral herpes or cold sores). It can also cause genital herpes. Most adults are infected with HSV-1. Type 2 (HSV-2) spreads by sexual contact and causes genital herpes.

Genital Herpes Drugs Uptake and Pipeline Development Activities:
The drugs uptake section focuses on the rate of uptake of potential drugs recently launched or expected to be launched during the study period. The report covers market uptake by drugs, patient uptake by therapies, and sales of each drug. Additionally, it provides insights into Genital Herpes Pipeline Development Activities, analyzing therapeutic candidates in various stages and key companies involved.

For more information about Genital Herpes companies working in the treatment market, visit: https://www.delveinsight.com/sample-request/genital-herpes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Genital Herpes Therapies and Key Companies:
Famciclovir, Aciclovir: EMS
Famciclovir: Novartis Pharmaceuticals
ASP2151, valacyclovir: Astellas Pharma Inc
Valaciclovir, Placebo: GlaxoSmithKline
HerpV and QS-21: Agenus Inc.
3% SPL7013 Gel (VivaGel): Starpharma Pty Ltd
PRO 2000/5: Endo Pharmaceuticals
Capsaicin Dermal Patch: NeurogesX

Genital Herpes Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Genital Herpes.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/genital-herpes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Genital Herpes Epidemiology Segmentation:
The Genital Herpes market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Genital Herpes Total Prevalence
Genital Herpes Prevalent Cases by severity
Genital Herpes Gender-specific Prevalence
Genital Herpes Diagnosed Cases of Episodic and Chronic

Genital Herpes Market Drivers:
Increasing Prevalence of Genital Herpes
Advancements in Antiviral Treatments
Rising Awareness and Diagnosis
Growing Investment in Vaccine Development

Genital Herpes Market Barriers:
Social Stigma and Lack of Awareness
Regulatory Hurdles for New Therapies and Vaccines
Risk of Viral Resistance

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/genital-herpes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Genital Herpes Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Genital Herpes Companies: AiCuris, Heidelberg ImmunoTherapeutics, BioNTec, EMS, Novartis Pharmaceuticals, Astellas Pharma Inc, Vical, GlaxoSmithKline, Genocea Biosciences, Inc., Agenus Inc., Starpharma Pty Ltd, Endo Pharmaceuticals, AiCuris Anti-infective Cures AG, NeurogesX.
Key Genital Herpes Therapies: Famciclovir, Aciclovir, valacyclovir, ASP2151, AIC316, Capsaicin Dermal Patch.
Genital Herpes Therapeutic Assessment: Current marketed and emerging therapies
Genital Herpes Market Dynamics: Genital Herpes Market drivers and Genital Herpes barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Genital Herpes Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Genital Herpes market outlook, drug uptake, treatment scenario, and epidemiology trend: https://www.delveinsight.com/sample-request/genital-herpes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 Executive Summary of Genital Herpes
4 Key Events
5 Genital Herpes Epidemiology and Market Forecast Methodology
6 Genital Herpes Market Overview at a Glance
7 Disease Background and Overview: Genital Herpes
8 Treatment and Management
9 Epidemiology and Patient Population of Genital Herpes in the 7MM
10 Patient Journey
11 Emerging Therapies
12 Genital Herpes: Seven Major Market Analysis
13 Unmet Needs
14 SWOT Analysis
15 KOL Views
16 Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

List of TOP Selling Inhibitors Market Research Report as of 2024:

CTLA-4 Inhibitors Market: https://www.delveinsight.com/report-store/ctla4-inhibitors-market-forecast
VEGF Inhibitors Market: https://www.delveinsight.com/report-store/vegf-inhibitors-market-forecast
TROP-2 Inhibitors Market: https://www.delveinsight.com/report-store/trop2-inhibitors-market-forecast
HER2+ Market: https://www.delveinsight.com/report-store/her2-positive-market-forecast
HER3+ Market: https://www.delveinsight.com/report-store/her3-positive-market-forecast
FTase Inhibitors Market: https://www.delveinsight.com/report-store/ftase-inhibitors-market-forecast
Bispecifics Market: https://www.delveinsight.com/report-store/bispecifics-market-forecast
CAR-T Market: https://www.delveinsight.com/report-store/car-t-market-forecast
CD-19 Market: https://www.delveinsight.com/report-store/cd19-market-forecast
CD-20 Market: https://www.delveinsight.com/report-store/cd20-market-forecast
CD-38 Market: https://www.delveinsight.com/report-store/cd38-market-forecast
TP-53 Market: https://www.delveinsight.com/report-store/tp53-market-forecast
NTRK Market: https://www.delveinsight.com/report-store/ntrk-market-forecast
BRCA Market: https://www.delveinsight.com/report-store/brca-market-forecast
SMAD4/DPC4 Market: https://www.delveinsight.com/report-store/smad4-dpc4-market-forecast
Connective Tissue Growth Factor (CTGF) Inhibitors Market: https://www.delveinsight.com/report-store/connective-tissue-growth-factor-ctgf-inhibitors-market-forecast
Selective Inhibitor of the CXCR4 Chemokine Receptor Market: https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
PI3K Market: https://www.delveinsight.com/report-store/pi3k-market-forecast
FGFR Market: https://www.delveinsight.com/report-store/fgfr-market-forecast
PROTAC Market: https://www.delveinsight.com/report-store/protac-market-forecast
CEACAM5 Market: https://www.delveinsight.com/report-store/ceacam5-market-forecast
Anti Cancer Vaccine Market: https://www.delveinsight.com/report-store/anti-cancer-vaccine-market-forecast
Androgen Receptor Inhibitor Market: https://www.delveinsight.com/report-store/androgen-receptor-inhibitor-market-forecast
GnRH Receptor Antagonist Market: https://www.delveinsight.com/report-store/gnrh-receptor-antagonist-market-forecast
CDK4/6 Inhibitor Market: https://www.delveinsight.com/report-store/cdk4-6-inhibitor-market-forecast
SERD Market: https://www.delveinsight.com/report-store/serd-market-forecast
AKT Inhibitor Market: https://www.delveinsight.com/report-store/akt-inhibitor-market-forecast
Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
B7-H3 Market: https://www.delveinsight.com/report-store/b7-h3-market-forecast
CYP17 Inhibitor Market: https://www.delveinsight.com/report-store/cyp17-inhibitor-market-forecast
NTD AR Inhibitor Market: https://www.delveinsight.com/report-store/ntd-ar-inhibitor-market-forecast
NRG fusion Market: https://www.delveinsight.com/report-store/nrg-fusion-market-forecast
AXL Receptor Tyrosine Kinase Inhibitors Market: https://www.delveinsight.com/report-store/axl-receptor-tyrosine-kinase-inhibitors-market-forecast
PSMA-Targeted Therapy Market: https://www.delveinsight.com/report-store/psma-targeted-therapy-market-forecast
EGFR Market: https://www.delveinsight.com/report-store/egfr-market-forecast
ALK Market: https://www.delveinsight.com/report-store/alk-market-forecast
BRAF Market: https://www.delveinsight.com/report-store/braf-market-forecast
ERBB 2 Receptor Antagonists Market: https://www.delveinsight.com/report-store/erbb2-receptor-antagonists-market-forecast
VEGFR-2 Inhibitor Market: https://www.delveinsight.com/report-store/vegfr2-inhibitor-market-forecast
Thymidine Phosphorylase Inhibitors Market: https://www.delveinsight.com/report-store/thymidine-phosphorylase-inhibitors-market-forecast
DNA Synthesis Inhibitor Market: https://www.delveinsight.com/report-store/dna-synthesis-inhibitor-market-forecast
CD223 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd223-antigen-inhibitors-market-forecast
BTK Inhibitors Market: https://www.delveinsight.com/report-store/btk-inhibitors-market-forecast
SERMS Market: https://www.delveinsight.com/report-store/serms-market-forecast
PLK1 Inhibitor Market: https://www.delveinsight.com/report-store/plk1-inhibitor-market-forecast
CD47 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd47-antigen-inhibitors-market-forecast
RET Fusion Market: https://www.delveinsight.com/report-store/ret-fusion-market-forecast
ROS-1 Market: https://www.delveinsight.com/report-store/ros1-market-forecast
Mesenchymal-epithelial Transition Factor (MET) Market: https://www.delveinsight.com/report-store/mesenchymal-epithelial-transition-factor-met-market-forecast
MET Kinase Inhibitor Market: https://www.delveinsight.com/report-store/met-kinase-inhibitor-market-forecast

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.